This medical device company develops a mobile phototherapy system for treating neonatal jaundice. Their product enables continuous treatment without separating newborns from parents, improving outcomes for jaundiced infants while supporting parent-child bonding.
Funding
Funding not disclosed
Founders
Product
Problem
Neonatal jaundice, a common condition in newborns, often requires phototherapy treatment, which traditionally involves separating the infant from the parents for extended periods. This separation can disrupt parent-child bonding and negatively impact both infant and parental well-being.
Solution
KidTech develops a mobile phototherapy system designed to treat neonatal jaundice without requiring continuous separation of newborns from their parents. The system allows for continuous treatment, enabling infants to remain with their parents, thus fostering parent-child bonding. This approach aims to improve outcomes for jaundiced infants by minimizing stress and promoting a more natural and supportive care environment. The portability of the system facilitates treatment in various settings, enhancing accessibility and convenience for both healthcare providers and families.
Target Audience
The primary target audience includes hospitals, neonatal intensive care units (NICUs), and healthcare providers specializing in newborn care.
Features
- Mobile phototherapy unit allowing for continuous treatment.
- Design promotes parent-child bonding by eliminating the need for separation during treatment.
- Portable system enables treatment in multiple settings.